In our study, we show that PRMT5 could activate Akt in colorectal cancer cells independent of ERK1/2, PTEN, and mTOR signaling, using PRMT5 stable knockdown cell lines and specific inhibitor GSK591, which is required for PRMT5 enzyme activity (Figure 4). The gene discussed is MAPK3; the disease is colorectal cancer.